Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors

Related Experiment Video

Updated: Sep 27, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

J M Hamby1, H D Showalter

  • 1Department of Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co., Ann Arbor, MI 48105, USA.

Pharmacology & Therapeutics
|August 24, 1999
PubMed

Insights

This review explores small molecule inhibitors of tumor angiogenesis, a promising new approach for anticancer therapies with potential for improved efficacy and reduced toxicity.

Area of Science:

  • Oncology and Molecular Biology
  • Focuses on the critical role of angiogenesis in tumor growth and metastasis.

Background:

  • Tumor cells rely on neovascularization for growth and spread.
  • Angiogenesis inhibition presents a novel therapeutic strategy against cancer.
  • Small molecule inhibitors are emerging as key players in anti-angiogenic research.

Purpose of the Study:

  • To review small molecule inhibitors of tumor-promoted angiogenesis.
  • To focus on literature from mid-1996 to mid-1998 with robust biological data.
  • To discuss historical context and key issues in the field of angiogenesis inhibition.

Main Methods:

  • Literature review of scientific publications.
  • Selection of studies with sufficient biological data on small molecule anti-angiogenic activity.
  • Analysis of small molecule inhibitors targeting tumor angiogenesis.

Main Results:

  • Identified numerous small molecules exhibiting anti-angiogenic properties.
  • Highlighted the potential of these inhibitors in preclinical research.
  • Demonstrated the growing body of evidence supporting anti-angiogenic therapies.

Conclusions:

  • Small molecule inhibitors of tumor angiogenesis represent a significant advancement in cancer therapy research.
  • These agents offer a promising alternative to conventional treatments with potential for enhanced efficacy and reduced side effects.
  • Further research into small molecule inhibitors is crucial for developing effective anticancer strategies.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: